[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasopharangeal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasopharangeal-cancer":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,66,98,126,149,172,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100602476","destiny-pantumour04-100602476",false,"NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","ALL","18 Years","130 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","RECRUITING","2026-06-26",{"date":56,"type":57},"2026-06-29","ACTUAL",{"date":59,"type":57},"2025-09-18",{"date":61,"type":22},"2028-03-30",{"name":63,"class":64},"AstraZeneca","INDUSTRY",17,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100617970","phase-2-ldrt-combined-with-toripalimab-and-chemotherapy-for-recurrentmetastatic-npc-100617970","NCT07325539","LDRT Combined With Toripalimab and Chemotherapy for Recurrent\u002FMetastatic NPC","Low-dose Radiotherapy (LDRT) Combined With Toripalimab and GP Chemotherapy for Recurrent\u002FMetastatic Nasopharyngeal Carcinoma (LIGHT): A Multicentre, Open-Label, Single-Arm Phase II Clinical Study","LIGHT","Inclusion Criteria:\n\n* Age: 18-65 years old.\n* Histologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II or III).\n* ECOG Performance Status score of 0-1.\n* At least one measurable lesion as per RECIST v1.1 criteria.\n* Patients with newly diagnosed metastatic NPC, or patients with locoregionally advanced NPC who developed metastasis ≥6 months or recurrence ≥12 months after completing radical radiotherapy\u002Fchemotherapy for the primary lesion.\n* No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent\u002Fmetastatic lesions.\n* Adequate organ function, meeting the following criteria within 7 days prior to treatment:\n\n  1. Hematological criteria (without transfusion or hematopoietic growth factor support within 14 days):\n\n     1. Hemoglobin (Hb) ≥90 g\u002FL.\n     2. White Blood Cell (WBC) count ≥4.0 × 10⁹\u002FL.\n     3. Platelet count (PLT) ≥100 × 10⁹\u002FL.\n  2. Biochemical criteria:\n\n     1. Total Bilirubin (TBIL) ≤1.5 × Upper Limit of Normal (ULN).\n     2. Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤2.5 × ULN.\n     3. Serum Creatinine (Cr) ≤1.5 × ULN AND Creatinine Clearance (CCr) ≥60 mL\u002Fmin.\n  3. Coagulation function: INR and APTT ≤1.5 × ULN.\n  4. Normal results for myocardial injury markers, heart failure markers, and electrocardiogram (ECG). For patients with abnormal results in any of these, the investigator will assess the need for Doppler echocardiography.\n  5. Thyroid function: TSH ≤ ULN. If abnormal, FT3 and FT4 levels should be considered; patients can be enrolled if FT3 and FT4 levels are normal.\n* Women of childbearing potential must have used reliable contraception, have a negative serum pregnancy test within 7 days before enrollment, and be willing to use adequate contraception during the trial and for 8 weeks after the last dose of the study drug, or be surgically sterile. Men must agree to use adequate contraception or be surgically sterile during the trial and for 8 weeks after the last dose.\n* Voluntary provision of signed informed consent, with good compliance.\n\nExclusion Criteria:\n\n* Disease progression within 6 months after completing standard treatment for locoregionally advanced nasopharyngeal carcinoma.\n* Absence of identifiable tumor lesions in both the primary site and locoregional lymph nodes, precluding the development of an LDRT plan.\n* Inability to undergo MRI due to reasons such as implanted metal devices or claustrophobia.\n* Requirement for systemic use of corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose or during the study. Inhaled or topical steroids and adrenal replacement steroid doses \\>10 mg\u002Fday prednisone equivalent are permitted in the absence of active autoimmune disease. Physiological replacement doses of corticosteroids (≤10 mg\u002Fday prednisone equivalent) are allowed.\n* Recurrent target lesions suitable for curative surgery or a second course of radiotherapy.\n* History of any active autoimmune or autoimmune disease, or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. Exceptions include type I diabetes, hypothyroidism requiring hormone replacement therapy, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia).\n* Active or uncontrolled severe infection (≥CTCAE Grade 3) within 4 weeks prior to enrollment.\n* History of active tuberculosis within the past year, regardless of treatment. Patients with a history of active pulmonary tuberculosis over 1 year ago who have documented evidence of adequate past anti-tuberculosis treatment may be considered; otherwise, they are excluded.\n* History of hypertension that cannot be adequately controlled with a single antihypertensive medication (systolic BP ≥150 mmHg or diastolic BP ≥90 mmHg).\n* Clinically significant bleeding symptoms or definite bleeding tendency, specifically excluding cases of local recurrence with high bleeding risk or cases within 1 year post-radiotherapy assessed to have a high risk of necrosis.\n* Urinalysis showing urine protein ≥ ++ AND confirmed 24-hour urine protein ≥1.0 g.\n* Myocardial ischemia (above Grade I), myocardial infarction, arrhythmia (including QTc ≥480 ms), or ≥ Grade 2 congestive heart failure (NYHA classification) within 6 months prior to enrollment.\n* If an echocardiogram is required per Inclusion Criterion 7(4), results showing Left Ventricular Ejection Fraction (LVEF) below the lower limit of normal (60%).\n* Diagnosis of other malignancies within 5 years prior to enrollment, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.\n* Presence of leptomeningeal or central nervous system metastases.\n* HIV positive, TP positive, liver cirrhosis, decompensated liver disease, active hepatitis (uncontrolled active hepatitis despite treatment: Hepatitis B - HBsAg positive and HBV DNA ≥1 × 10⁴ copies\u002FmL; Hepatitis C - HCV RNA positive with abnormal liver function; co-infection with HBV and HCV) requiring antiviral therapy.\n* Participation in another anti-tumor drug clinical trial within 4 weeks prior to enrollment.\n* Administration of any live attenuated vaccine within 30 days prior to enrollment.\n* Contraindications to radiotherapy.\n* Known allergy to the study drug or any of its excipients, or history of severe allergic reactions to other monoclonal antibodies.\n* History of psychoactive drug abuse unable to be abstained, or presence of psychiatric disorders.\n* Any other condition assessed by the investigator as potentially endangering the patient's safety or compliance, including severe concurrent diseases (including psychiatric disorders) requiring prompt treatment, severely abnormal laboratory test results, or other psychological, familial, or sociological factors deemed high-risk.","65 Years",{"count":76,"type":22},55,"INTERVENTIONAL",[79],"PHASE2","This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II clinical trial.",[82,38],"Nasopharyngeal Cancinoma (NPC)",[84,85,86],"PD-1 antibody","Low dose radiotherapy","Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","2026-05-20",{"date":89,"type":57},"2026-05-22",{"date":91,"type":57},"2026-01-12",{"date":93,"type":22},"2030-01-30",{"name":95,"class":96},"Sun Yat-sen University","OTHER",2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":77,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100635991","phase-3-topical-chlorhexidine-spray-for-the-prevention-of-acute-radiation-dermatitis-in-patients-with-nasopharyngeal-carcinoma-100635991","NCT07559877","Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:","Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma: A Phase III Randomized Double-Blind Single-Center Trial","Inclusion Criteria:\n\nHistologically or cytologically confirmed nasopharyngeal carcinoma. Clinical stage II-III disease with N≥1, according to the UICC\u002FAJCC 9th edition. Planned to receive first-course definitive chemoradiotherapy, with a total radiotherapy dose of 60-70 Gy.\n\nAble to communicate and complete study assessments. Willing to participate and able to provide written informed consent. Eligible based on baseline assessments performed before chemoradiotherapy.\n\nExclusion Criteria:\n\n* History of or current psychiatric disorder, cognitive impairment, or other severe organic disease.\n\nPresence of another concomitant malignancy. Receipt of any other prophylactic intervention for radiation dermatitis. Pre-existing skin disease before chemoradiotherapy. Known hypersensitivity or allergy to chlorhexidine.","75 Years",{"count":107,"type":22},148,[109],"PHASE3","This study investigated the effects of topical chlorhexidine spray on the incidence, severity, and quality of life during radiotherapy in nasopharyngeal carcinoma patients.",[38],[113,114,115],"Radiation Dermatitis Acute","Nasoharyngeal carcinoma","chlorhexidine","2026-04-23",{"date":118,"type":57},"2026-04-30",{"date":120,"type":22},"2026-04-01",{"date":122,"type":22},"2027-09-30",{"name":124,"class":96},"Jiangxi Provincial Cancer Hospital",1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":77,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":125},"100623106","phase-2-a-phase-ii-trial-comparing-immunotherapy-versus-capecitabine-maintenance-after-chemo-chemoradiotherapy-for-high-risk-nasopharyngeal-carcinoma-100623106","NCT07392320","A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","A Randomized, Open-Label, Phase II Clinical Study Comparing Immunotherapy Combined With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy Maintenance Versus Capecitabine Maintenance in Locally Advanced High-Risk Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Voluntary participation and written informed consent must be signed.\n* Age between 18 and 70 years, male or non-pregnant female.\n* Pathologically confirmed nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated type, i.e., WHO type II or type III).\n* Stage III disease (AJCC 9th edition staging) or pre-treatment plasma Epstein-Barr virus DNA (EBV DNA) ≥ 1500 copies\u002Fml.\n* Efficacy after 3 cycles of induction immunochemotherapy assessed as complete response (CR) or partial response (PR) by nasopharyngoscopy and contrast-enhanced MRI of the nasopharynx and neck.\n* ECOG performance status score of 0 or 1.\n* Adequate hematological function: Hemoglobin (HGB)≥90g\u002FL, White Blood Cell (WBC) ≥ 4.010\\^9\u002FL, and Platele (PLT) ≥10010\\^9\u002FL.\n* Adequate hepatic function: ALT and AST≤2.5Upper Limit of Normal (ULN), total bilirubin ≤2.0ULN, and serum albumin≥30g\u002FL.\n* Adequate renal function: Serum creatinine ≤ 1.5\\*ULN or calculated creatinine clearance (CrCl) ≥ 60 mL\u002Fmin (using the Cockcroft-Gault formula).\n* International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 \\*ULN (unless the subject is receiving anticoagulant therapy and the coagulation parameters (PT\u002FINR and APTT) are within the expected therapeutic range for the anticoagulant at the time of screening).\n\nExclusion Criteria:\n\n* Patients with recurrent or distant metastatic nasopharyngeal carcinoma.\n* Pathological diagnosis of keratinizing squamous cell carcinoma (WHO Type I).\n* Patients who have previously received radiotherapy or systemic chemotherapy.\n* Women who are pregnant or breastfeeding, or individuals of childbearing potential who are not using effective contraception.\n* HIV positive.\n* History of other malignancies (except for cured basal cell carcinoma or cervical carcinoma in situ).\n* Patients who have previously received immune checkpoint inhibitors (e.g., CTLA-4, PD-1, PD-L1 inhibitors).\n* Patients with immunodeficiency diseases or a history of organ transplantation.\n* History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n* Patients who have received high-dose glucocorticoids, anticancer monoclonal antibodies, or other immunosuppressive therapy within 4 weeks.\n* Patients with significantly impaired cardiac, hepatic, pulmonary, renal, or bone marrow function.\n* Patients with severe, uncontrolled medical conditions or infections.\n* Concurrent use of other investigational drugs or participation in another clinical trial.\n* Refusal or inability to sign the informed consent form for trial participation.\n* Patients with other contraindications to the treatment.\n* Patients with personality or psychiatric disorders, or those lacking or with limited legal capacity.\n* Patients who are hepatitis B surface antigen (HBsAg) positive with peripheral blood hepatitis B virus DNA (HBV DNA) ≥ 1000 copies\u002Fml. Patients who are HBsAg positive but have HBV DNA \\\u003C 1000 copies\u002Fml are eligible if the investigator determines that their chronic hepatitis B is stable and does not pose an increased risk.\n* Patients with a positive HCV antibody test result, unless the polymerase chain reaction (PCR) test for HCV RNA is negative.","70 Years",{"count":135,"type":22},142,[79],"In this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies\u002Fml, AJCC 9th edition) that is sensitive to chemotherapy and PD-1 monoclonal antibody therapy. The trial compares sequential treatment with the TP regimen combined with PD-1 monoclonal antibody followed by concurrent chemoradiotherapy and PD-1 maintenance therapy versus capecitabine maintenance therapy. The aim is to provide high-quality clinical evidence for optimizing the treatment strategy for high-risk locally advanced nasopharyngeal carcinoma.",[38],[140],"high-risk locally advanced nasopharyngeal carcinoma","2026-04-22",{"date":143,"type":57},"2026-04-24",{"date":145,"type":57},"2026-02-10",{"date":147,"type":22},"2033-02-10",{"name":95,"class":96},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":156,"targetDuration":4,"studyType":77,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":125},"100618486","phase-2-pd-1-inhibitor-plus-chemotherapy-followed-by-immediate-versus-selective-re-irradiation-for-locally-advanced-recurrent-npc-100618486","NCT07332247","PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","An Open-Label, Randomized Controlled Phase II Clinical Trial of PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-70 years, any gender.\n2. Local recurrence (with or without regional recurrence) more than one year after radical treatment and unsuitable for surgery.\n3. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO type II or III).\n4. Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy.\n5. ECOG performance status 0-1.\n6. Expected survival ≥ 3 months.\n7. No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent nasopharyngeal carcinoma\n8. No contraindications to immunotherapy, chemotherapy, or re-irradiation.\n9. Adequate organ function within 14 days before first dose, defined as:\n\n   Hematology：Hemoglobin ≥ 90 g\u002FL，ANC ≥ 1.5 × 10⁹\u002FL，Platelet count ≥ 100 × 10⁹\u002FL Renal Function：Creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) \u002F eGFR ≥ 60 mL\u002Fmin Liver Function：Total bilirubin ≤ 1.5 × ULN，AST and ALT ≤ 2.5 × ULN, or ≤ 5 × ULN in the presence of liver metastases\n10. INR or PT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range，APTT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range.\n\nExclusion Criteria:\n\n1. Presence of grade 3 or higher late radiation toxicity (excluding skin, subcutaneous tissue, and mucosa) at the time of recurrence\n2. Prior anti-tumor therapy for recurrent nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy.\n3. Prior treatment with PD-1\u002FPD-L1 or CTLA-4 inhibitors.\n4. History of other malignancies within the past 5 years, except adequately treated basal cell carcinoma, squamous cell skin cancer, or in-situ cervical cancer.\n5. Active autoimmune disease or history of autoimmune disease requiring systemic treatment (e.g., corticosteroids, immunosuppressants) within the past 2 years, except for stable hypothyroidism, type 1 diabetes mellitus, or resolved childhood asthma\u002Fatopy.\n6. Known history of active pulmonary tuberculosis (TB). Suspected active TB must be excluded by chest X-ray, sputum examination, and assessment of clinical signs and symptoms.\n7. Hepatitis B: HBsAg positive with peripheral blood HBV DNA ≥ 1000 copies\u002FmL\n8. Hepatitis C: HCV antibody positive, eligible only if HCV RNA is negative\n9. HIV infection\n10. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, myocardial infarction within 6 months, congestive heart failure ≥ NYHA class II, or serious arrhythmia).\n11. Interstitial lung disease, non-infectious pneumonitis, or history of ≥ grade 2 pneumonitis.\n12. Major surgery within 4 weeks before enrollment, or unhealed surgical wound.\n13. Pregnant or breastfeeding women, or those planning pregnancy during the study period.\n14. Known allergy or hypersensitivity to study drugs or their excipients.\n15. Any condition that, in the investigator's judgment, would interfere with trial participation or interpretation of results.",{"count":157,"type":22},94,[79],"This phase II randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation in locally advanced recurrent nasopharyngeal carcinoma. The study aims to determine whether sequential radiotherapy provides additional survival benefit beyond systemic immunochemotherapy.",[38,161],"Recurrent Nasopharynx Carcinoma",[163],"Locally Advanced Recurrent Nasopharyngeal Carcinoma","2026-02-02",{"date":166,"type":57},"2026-02-04",{"date":168,"type":22},"2026-02-03",{"date":170,"type":22},"2035-02-03",{"name":95,"class":96},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":179,"targetDuration":4,"studyType":77,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100611033","phase-3-pd-1-inhibitor-plus-chemotherapy-followed-by-immediate-versus-salvage-locoregional-radiotherapy-in-de-novo-metastatic-npc-100611033","NCT07235319","PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","A Multicenter, Open-Label, Randomized Phase III Non-Inferiority Trial of PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-70 years, any gender.\n2. Histologically confirmed differentiated non-keratinizing carcinoma or undifferentiated non-keratinizing carcinoma by tissue biopsy, with radiologically detectable metastatic lesions. Pathological confirmation of metastatic lesions is recommended but not mandatory.\n3. ECOG performance status 0-1.\n4. Stage IV NPC according to the 9th edition of the UICC\u002FAJCC staging system.\n5. No prior anti-tumor treatment for NPC (radiotherapy, chemotherapy, surgery, etc.).\n6. Expected survival ≥ 3 months.\n7. At least one measurable lesion per RECIST v1.1.\n8. Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy.\n9. Adequate organ function within 14 days before first dose, defined as:\n\n   Hematology：Hemoglobin ≥ 90 g\u002FL，ANC ≥ 1.5 × 10⁹\u002FL，Platelet count ≥ 100 × 10⁹\u002FL Renal Function：Creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) \u002F eGFR ≥ 60 mL\u002Fmin Liver Function：Total bilirubin ≤ 1.5 × ULN，AST and ALT ≤ 2.5 × ULN, or ≤ 5 × ULN in the presence of liver metastases\n10. INR or PT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range，aPTT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range\n\nExclusion Criteria:\n\n1. Prior anti-tumor therapy for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy.\n2. Prior treatment with PD-1\u002FPD-L1 or CTLA-4 inhibitors.\n3. Presence of uncontrolled or symptomatic central nervous system (CNS) metastases.\n4. History of other malignancies within the past 5 years, except adequately treated basal cell carcinoma, squamous cell skin cancer, or in-situ cervical cancer.\n5. Active autoimmune disease or history of autoimmune disease requiring systemic treatment (e.g., corticosteroids, immunosuppressants) within the past 2 years, except for stable hypothyroidism, type 1 diabetes mellitus, or resolved childhood asthma\u002Fatopy.\n6. Known history of active pulmonary tuberculosis (TB). Suspected active TB must be excluded by chest X-ray, sputum examination, and assessment of clinical signs and symptoms.\n7. Hepatitis B: HBsAg positive with peripheral blood HBV DNA ≥ 1000 copies\u002FmL\n8. Hepatitis C: HCV antibody positive, eligible only if HCV RNA is negative\n9. HIV infection\n10. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, myocardial infarction within 6 months, congestive heart failure ≥ NYHA class II, or serious arrhythmia).\n11. Interstitial lung disease, non-infectious pneumonitis, or history of ≥ grade 2 pneumonitis.\n12. Major surgery within 4 weeks before enrollment, or unhealed surgical wound.\n13. Pregnant or breastfeeding women, or those planning pregnancy during the study period.\n14. Known allergy or hypersensitivity to study drugs or their excipients.\n15. Any condition that, in the investigator's judgment, would interfere with trial participation or interpretation of results.",{"count":180,"type":22},260,[109],"This phase III randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus salvage locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma. The study aims to evaluate whether salvage locoregional radiotherapy is non-inferior to immediate radiotherapy following PD-1 inhibitor plus GP in de novo metastatic NPC, with potential for reduced toxicity.",[38,184],"Distant Metastasis",[186],"Locoregional radiotherapy","2025-11-17",{"date":189,"type":57},"2025-11-19",{"date":191,"type":22},"2025-11-20",{"date":193,"type":22},"2034-11-20",{"name":95,"class":96},5,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":203,"targetDuration":4,"studyType":77,"phases":205,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100611283","phase-3-phase-iii-trial-of-ebv-dna-guided-adaptive-immunotherapy-for-advanced-nasopharyngeal-carcinoma-100611283","NCT07238569","Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma","Multicenter, Prospective Phase III Clinical Trial of EBV-DNA-Guided Adaptive Immunotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age ≥18 and ≤65 years\n2. Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria.\n3. Eastern Cooperative Oncology Group performance score of 0-1.\n4. Tumor staged as II-III disease (AJCC 9th edition), excluding T3N0-1.\n5. Adequate marrow function: white blood cell count \\> 4 × 10⁹\u002FL hemoglobin \\>90g\u002FL and platelet count \\>100×10⁹\u002FL\n6. Adequate hepatic and renal function：\n\n   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n   * Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×ULN\n   * Alkaline phosphatase ≤ 2.5 × ULN\n   * clearance rate ≥ 60 ml\u002Fmin\n7. Other laboratory and clinical criteria\n\n   * Normal thyroid function, serum amylase and lipase, pituitary hormone levels, inflammatory markers, cardiac enzyme tests and electrocardiogram (ECG)\n   * For patients aged \\>50 years with a history of smoking, normal pulmonary function test (PFT) results are required\n   * For patients with abnormal ECG findings or a prior history of cardiovascular disease (not meeting any exclusion criteria listed in Item 8), additional assessments including myocardial function evaluation and cardiac ultrasound (echocardiography) must be performed, with results within normal limits\n8. Patients with persistent EBV DNA positivity or stable disease following 3 cycles of induction chemotherapy (gemcitabine, cisplatin, and adebrelimab).\n9. Patients must be informed of the investigational nature of this study and give written informed consent, and be willing and able to comply with the study schedule, including follow-up visits, treatment procedures, laboratory testing, and other protocol-related requirements.\n10. Women of childbearing potential (WOCBP) must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).\n\nExclusion Criteria:\n\n1. Disease progression after induction chemotherapy\n2. Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA \\>1×103 copies\u002FmL, positive for anti-hepatitis C virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody\n3. Positive for anti-HIV antibody or diagnosed with acquired immunodeficiency syndrome (AIDS).\n4. Active pulmonary tuberculosis: Patients with a history of active tuberculosis within the past year should be excluded regardless of treatment status. Patients with a history of active pulmonary tuberculosis more than one year prior should also be excluded, unless they received confirmed and regular anti-tuberculosis treatment.\n5. Active, known, or suspected autoimmune diseases, including but not limited to uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilators. Type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are allowed.\n6. History of interstitial lung disease or pneumonia requiring oral or intravenous corticosteroids within the past year; use of vancomycin within the past month.\n7. Ongoing chronic systemic corticosteroid therapy (equivalent to or greater than prednisone \\>10mg per day) or any other immunosuppressive therapy. Patients received inhale or topical corticosteroid are allowed.\n8. Uncontrolled cardiac conditions, such as:\n\n   * Heart failure with New York Heart Association (NYHA) classification ≥ Class II;\n   * Unstable angina;\n   * History of myocardial infarction within the past year;\n   * Supraventricular or ventricular arrhythmias requiring treatment or intervention\n9. Pregnant or breastfeeding women (pregnancy testing should be considered for women of childbearing potential with active sexual life)\n10. History or presence of other malignancies, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.\n11. Known hypersensitivity to macromolecule protein products or any component of adebrelimab.\n12. Active infections requiring systemic treatment within 1 week prior to enrollment.\n13. Administration of live vaccines within 30 days prior to the first dose of adebrelimab.\n14. Factors significantly affecting the absorption of oral drugs, such as inability to swallow, chronic diarrhea, or intestinal obstruction.\n15. History of organ transplantation or hematopoietic stem cell transplantation.\n16. Any other condition assessed by the investigator as potentially compromising patient safety or compliance, such as severe illnesses requiring urgent treatment (including psychiatric disorders), significantly abnormal laboratory values, or other psychological, familial, or social risk factors.",{"count":204,"type":22},516,[109],"This trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA positivity or stable disease after three IC cycles. The control arm received adjuvant adebrelimab, while the experimental arm received adebrelimab plus capecitabine.",[82,38],[209,210,211,212],"adebrelimab","PD-L1 antibody","chemoradiotherapy","capecitabine","NOT_YET_RECRUITING","2025-11-16",{"date":191,"type":57},{"date":217,"type":22},"2025-12-01",{"date":219,"type":22},"2031-05-23",{"name":95,"class":96}]